4.6 Article

Derepression of the USP22-FASN axis by p53 loss under oxidative stress drives lipogenesis and tumorigenesis

期刊

CELL DEATH DISCOVERY
卷 8, 期 1, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41420-022-01241-9

关键词

-

资金

  1. National Natural Science Foundation of China [82203254, 31871406]
  2. Natural Science Foundation of Guangdong Province [2021A1515011067]
  3. Yangjiang People's Hospital [2021002]
  4. Special Funds for Scientific and Technological Innovation Cultivation of College Students in Guangdong Province

向作者/读者索取更多资源

This study reveals the role of ROS in regulating lipid synthesis during colorectal tumorigenesis through a p53-dependent mechanism. The USP22-FASN axis is identified as an important pathway in this process, and targeting this axis may represent a potential strategy for the treatment of colorectal cancer.
Overproduction of reactive oxygen species (ROS) and aberrant lipid metabolism are established hallmarks of cancer; however, the role of ROS in lipid synthesis during tumorigenesis is almost unknown. Herein, we show that ROS regulates lipid synthesis and thus controls colorectal tumorigenesis through a p53-dependent mechanism. In p53 wild-type colorectal cancer (CRC) cells, hydrogen peroxide (H2O2)-induced p53 expression represses the transcription of deubiquitinase USP22, which otherwise deubiquitinates and stabilizes Fatty Acid Synthase (FASN), and thus inhibits fatty acid synthesis. Whereas, in p53-deficient CRC cells, ROS-mediated inhibition of USP22 is relieved, leading to FASN stabilization, which thus promotes lipid synthesis and tumor growth. In human CRC specimens, USP22 expression is positively correlated with FASN expression. Our study demonstrates that ROS critically regulates lipid synthesis and tumorigenesis through the USP22-FASN axis in a p53-dependent manner, and targeting the USP22-FASN axis may represent a potential strategy for the treatment of colorectal cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据